BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
Key Highlights
- ➤November 13 presentation will disclose previously unshared bezisterim biomarker data
- ➤203-patient Phase 2 ADDRESS-LC trial missed statistical significance across the overall population
- ➤High-symptom subgroups showed statistically significant improvements across multiple measures
- ➤Approximately 78% of participants had severe fatigue, PEM, or cognitive impairment
- ➤$13.13 million Department of War grant fully funds the Long COVID study
Expert Statements
Penelope Markham, Senior Vice President and Program Lead for Long COVID at BioVie
“We look forward to presenting initial biomarker data at the upcoming Long COVID conference that are consistent with the clinical findings observed in ADDRESS-LC. The biomarkers provide further biological support for the potential of bezisterim in treating Long COVID. Our Trial observed a consistent and clinically coherent pattern of improvement across measures of fatigue, post-exertional malaise, clinician- and patient-reported outcomes, and objective measures of cognition function among patients with greater baseline symptom burden.”
CARSON CITY, Nev., Nov. 02, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has been invited to present a late-breaking oral presentation at the 4th Long COVID International Conference 2026 to be held in Nice, France from November 12-13, 2026.
Dr. Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID, will share the presentation titled “Bezisterim Improves Fatigue, Post-Exertional Malaise, and Cognition in Prespecified High-Symptom-Burden Subgroups of the Phase 2 Randomized ADDRESS-LC Trial in Long COVID” during the “Session 8: Clinical Trials” session, starting 3:30 p.m. on Friday, November 13. The presentation will include new biomarker data that has not been shared previously.
Get started
Create a free account to read the full story.